Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Hanan Jafar10 enrolled

Overview

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Knee Osteoarthrosis

Interventions

Wharton Jelly derived mesenchymal stem cellBIOLOGICAL

Intra-articular Wharton Jelly derived mesenchymal stem cell injection.

Eligibility

Sex: ALLMin age: 42 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Severe KOA stage III or IV by Laurance \& Kellgren staging as judged by Posterioranterior (PA) Xray of the knee joint. * Willing to participate by signing the informed consent Exclusion Criteria: 1. Sublaxation beyond 20 degrees of the bones of the knee joint 2. Oral anticoagulants or heparin therapy 3. Heart failure or arrhythmia 4. Body Mass Index \> 35 5. Uncontrolled Diabetes Mellitus. 6. Evidence of Infectious Diseases. 7. Active infection 8. Malignancy 9. Pregnancy 10. Anemia less than 11g/dl or thrombocytopenia less than 100,000 or leucopenia less than 3000. 11. Unreliable patients 12. Non-resident in Jordan

Locations (1)

Cell Therapy Center

Amman, Jordan

RECRUITING

Outcomes

Primary Outcomes

Evaluation of the safety and tolerability of the intra articular injection

patients will be monitored for any adverse events resulting from the intraarticular injection of WJMSC

Time frame: 6 months

Secondary Outcomes

Assessment of the efficacy of intra-articular injection of WJMSC

The efficacy of the intra-articular injection of WJMSC will be assessed by Magnetic Resonance Imaging (MRI).

Time frame: 12 months

Central Contacts

Hanan Jafar, PhD

CONTACT

00962798871087 hanan.jafar@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.